|
Market Closed -
Nasdaq
16:00:00 2026-09-14 EDT
|
5-day change | 1st Jan Change | ||
| 1.600 USD | -0.62% |
|
-10.61% | -78.26% |
| 08-31 | Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis | CI |
| 08-29 | Karyopharm Therapeutics Inc. - Special Call |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Biopharmaceuticals | -0.62% | -10.61% | -78.26% | -75.19% | -98.09% | 36.29M |  | | |
- Stock Market
- Stocks
- KPTI Stock
- Charts Karyopharm Therapeutics Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
